Stockreport

AVEO Oncology and EUSA Pharma Announce Presentation of Final PFS Results from Phase 2 Portion of the TiNivo Study in Renal Cell Carcinoma

AVEO Pharmaceuticals, Inc.  (AVEO) 
Last aveo pharmaceuticals, inc. earnings: 3/16 04:05 pm Check Earnings Report
US:NASDAQ Investor Relations: investor.aveooncology.com
PDF – Results Suggest Additive or Synergistic Activity in Both Treatment Naïve and Previously Treated Patients – -Tivozanib-Nivolumab Combination Generally Well Tolerated -– [Read more]